![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
METABOLISM, TRANSPORT, AND PHARMACOGENOMICS
Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina (S.R.F., T.-C.Z.); Pharmacogenetics Section, Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental and Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina (R.M., T.S., M.N.); Center for Molecular Toxicology and Carcinogenesis, Pennsylvania State University, University Park, Pennsylvania (C.J.O.); CellzDirect, Inc., Pittsboro, North Carolina (E.L.L.); and Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland (H.W.)
Both the human pregnane X receptor (hPXR) and constitutive androstane receptor (hCAR) are capable of regulating CYP3A4 and CYP2B6 gene expression. However, the majority of currently identified CYP3A4 and CYP2B6 inducers are confirmed activators of hPXR but not hCAR. To compare these receptors with respect to their chemical selectivities, 16 drugs known to induce CYP3A4 and/or CYP2B expression were evaluated for relative activation of hPXR versus hCAR. Because of the high basal but low chemical-induced activation of hCAR in immortalized cells, alternative methods were used to evaluate hCAR activation potential. Thirteen of the 16 compounds were classified as moderate to strong hPXR activators. In contrast, carbamazepine (CMZ), efavirenz (EFV), and nevirapine (NVP) were classified as negligible or weak hPXR activators at concentrations associated with efficacious CYP2B6 reporter or endogenous gene induction in primary human hepatocytes, suggesting potential activation of hCAR. Subsequent experiments demonstrated that these three drugs efficiently induced nuclear accumulation of in vivo-transfected enhanced yellow fluorescent protein-hCAR and significantly increased expression of a CYP2B6 reporter gene when hCAR was expressed in CAR–/– mice. In addition, using a recently identified, chemically responsive splice variant of hCAR (hCAR3), the hCAR activation profiles of the 16 compounds were evaluated. By combining results from the hPXR- and hCAR3-based reporter gene assays, these inducers were classified as hPXR, hCAR, or hPXR/hCAR dual activators. Our results demonstrate that CMZ, EFV, and NVP induce CYP2B6 and CYP3A4 preferentially through hCAR and that hCAR3 represents a sensitive tool for in vitro prediction of chemical-mediated human CAR activation.
Address correspondence to: Dr. Hongbing Wang, Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 21201-6808. E-mail: hwang{at}rx.umaryland.edu
This article has been cited by other articles:
|
|
 |
|
  A. H. Tolson, H. Li, N. D. Eddington, and H. Wang Methadone Induces the Expression of Hepatic Drug-Metabolizing Enzymes through the Activation of Pregnane X Receptor and Constitutive Androstane Receptor Drug Metab. Dispos., September 1, 2009; 37(9): 1887 - 1894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Chu, H. J. Einolf, R. Evers, G. Kumar, D. Moore, S. Ripp, J. Silva, V. Sinha, M. Sinz, and A. Skerjanec In Vitro and in Vivo Induction of Cytochrome P450: A Survey of the Current Practices and Recommendations: A Pharmaceutical Research and Manufacturers of America Perspective Drug Metab. Dispos., July 1, 2009; 37(7): 1339 - 1354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zhu, S. Kaul, P. Nandy, D. M. Grasela, and M. Pfister Model-Based Approach To Characterize Efavirenz Autoinduction and Concurrent Enzyme Induction with Carbamazepine Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2346 - 2353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kozawa, M. Honma, and H. Suzuki Quantitative Prediction of in Vivo Profiles of CYP3A4 Induction in Humans from in Vitro Results with a Reporter Gene Assay Drug Metab. Dispos., June 1, 2009; 37(6): 1234 - 1241. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Li, T. Chen, J. Cottrell, and H. Wang Nuclear Translocation of Adenoviral-Enhanced Yellow Fluorescent Protein-Tagged-Human Constitutive Androstane Receptor (hCAR): A Novel Tool for Screening hCAR Activators in Human Primary Hepatocytes Drug Metab. Dispos., May 1, 2009; 37(5): 1098 - 1106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. DeKeyser, M. C. Stagliano, S. S. Auerbach, K. S. Prabhu, A. D. Jones, and C. J. Omiecinski Di(2-ethylhexyl) phthalate Is a Highly Potent Agonist for the Human Constitutive Androstane Receptor Splice Variant CAR2 Mol. Pharmacol., May 1, 2009; 75(5): 1005 - 1013. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bousquet, A. Pruvost, A.-C. Guyot, R. Farinotti, and A. Mabondzo Combination of Tenofovir and Emtricitabine plus Efavirenz: In Vitro Modulation of ABC Transporter and Intracellular Drug Accumulation Antimicrob. Agents Chemother., March 1, 2009; 53(3): 896 - 902. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kwara, M. Lartey, K. W. Sagoe, F. Xexemeku, E. Kenu, J. Oliver-Commey, V. Boima, A. Sagoe, I. Boamah, D. J. Greenblatt, et al. Pharmacokinetics of Efavirenz When Co-administered With Rifampin in TB/HIV Co-infected Patients: Pharmacogenetic Effect of CYP2B6 Variation J. Clin. Pharmacol., September 1, 2008; 48(9): 1032 - 1040. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Li, T. Chen, J. D. Stanton, T. Sueyoshi, M. Negishi, and H. Wang The Peripheral Benzodiazepine Receptor Ligand 1-(2-Chlorophenyl-methylpropyl)-3-isoquinoline-carboxamide Is a Novel Antagonist of Human Constitutive Androstane Receptor Mol. Pharmacol., August 1, 2008; 74(2): 443 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Hariparsad, B. A. Carr, R. Evers, and X. Chu Comparison of Immortalized Fa2N-4 Cells and Human Hepatocytes as in Vitro Models for Cytochrome P450 Induction Drug Metab. Dispos., June 1, 2008; 36(6): 1046 - 1055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. Kharasch, D. Mitchell, R. Coles, and R. Blanco Rapid Clinical Induction of Hepatic Cytochrome P4502B6 Activity by Ritonavir Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1663 - 1669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. DiGiacinto, K. M. Chan-Tack, S. M. Robertson, K. S. Reynolds, and K. A. Struble Are Literature References Sufficient for Dose Recommendations? An FDA Case Study of Efavirenz and Rifampin J. Clin. Pharmacol., April 1, 2008; 48(4): 518 - 523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O Kummer, E Mossdorf, M Battegay, L Elzi, M Bodmer, S Krahenbuhl, and M Haschke Treatment of an atazanivir associated grade 4 hyperbilirubinaemia with efavirenz Gut, October 1, 2007; 56(10): 1477 - 1478. [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Hernandez, W. Huang, L. M. Chapman, S. Chua, D. D. Moore, and W. S. Baldwin The Environmental Estrogen, Nonylphenol, Activates the Constitutive Androstane Receptor Toxicol. Sci., August 1, 2007; 98(2): 416 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Afsharian, Y. Terelius, Z. Hassan, C. Nilsson, S. Lundgren, and M. Hassan The Effect of Repeated Administration of Cyclophosphamide on Cytochrome P450 2B in Rats Clin. Cancer Res., July 15, 2007; 13(14): 4218 - 4224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Cerveny, L. Svecova, E. Anzenbacherova, R. Vrzal, F. Staud, Z. Dvorak, J. Ulrichova, P. Anzenbacher, and P. Pavek Valproic Acid Induces CYP3A4 and MDR1 Gene Expression by Activation of Constitutive Androstane Receptor and Pregnane X Receptor Pathways Drug Metab. Dispos., July 1, 2007; 35(7): 1032 - 1041. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
